Logo

Genmab & Seagen Present Preliminary Results of Tivdak (tisotumab vedotin) in P-II (innovaTV 207) Trial for Head & Neck Squamous Cell Carcinoma at ASTRO 2022

Share this

Genmab & Seagen Present Preliminary Results of Tivdak (tisotumab vedotin) in P-II (innovaTV 207) Trial for Head & Neck Squamous Cell Carcinoma at ASTRO 2022

Shots:

  • The P-II (innovaTV 207) trial evaluates tisotumab vedotin as monothx. in 532 patients with SCCHN who experienced disease progression & 1L Pt-containing regimen & checkpoint inhibitor
  • The results showed a manageable safety profile & promising preliminary antitumor activity with the 1EPs of ORR (16%). The 2EPs included DCR, PFS/investigator (58.1%) & OS, m-PFS (4.2mos.) with a median follow-up (10.0mos.), m-OS (9.4mos.), AEs were consistent with the known safety profile of tisotumab vedotin
  • Additionally, 67.7% of patients has grade ≥3 TEAEs, treatment-emergent SAEs & treatment-related SAEs (51.6% & 6.5%). The therapy has received accelerated approval for cervical cancer in Sept 2021

 Ref: Globe Newswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions